RxDoctor Payments Data

Holly Malone

Nurse Practitioner · Pensacola, FLNPI 1447767009

Payments from drug & device makers

$7,497in general payments, 2019–2025

Across 275 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • AbbVie$969
  • Pfizer$543
  • Novo Nordisk$332
  • AstraZeneca$304
  • Lilly USA, LLC$236
  • plus $2K from 39 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$4,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,497 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$91,361
Medicare patients
362
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$70,954
EliquisApixaban49$63,220
OzempicSemaglutide42$53,115
JardianceEmpagliflozin32$38,863
FarxigaDapagliflozin Propanediol27$27,057
LinzessLinaclotide14$16,579
Praluent PenAlirocumab18$9,747
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,832
Omeprazole145$2,692
SynthroidLevothyroxine Sodium35$2,663
Gabapentin97$2,543
Duloxetine Hcl87$2,175
Atorvastatin Calcium185$1,868
Rosuvastatin Calcium191$1,731
Buspirone Hcl67$1,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$236$70,95467 claims
PfizerEliquis$543$63,22049 claims
Novo NordiskOzempic$332$53,11542 claims
Boehringer IngelheimJardiance$101$38,86332 claims
AstraZenecaFarxiga$304$27,05727 claims
AbbVieLinzess, Synthroid$969$19,24249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →